Onyx BiotecNSE:ONYX 13 ROE % is 2.49% as of Mar. 2026, which is 80% below its 10-year median of 12.25. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Onyx Biotec ranks worse than 56.27% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Onyx Biotec's annualized net income for the quarter that ended in Mar. 2026 was ₹13.7 Mil. Onyx Biotec's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹550.6 Mil. Therefore, Onyx Biotec's annualized ROE % for the quarter that ended in Mar. 2026 was 2.49%.
The historical rank and industry rank for Onyx Biotec's ROE % or its related term are showing as below:
NSE:ONYX'
s ROE % Range Over the Past 10 Years
Min: -0.39 Med: 12.25 Max: 20.47
Current: -0.39
During the past 5 years, Onyx Biotec's highest ROE % was 20.47%. The lowest was -0.39%. And the median was 12.25%.
NSE:ONYX's ROE % is ranked worse than 56.27% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.41
vs NSE:ONYX: -0.39
Onyx Biotec (NSE:ONYX) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Onyx Biotec ROE % Related Terms
Onyx Biotec ROE % Historical Data
* Premium members only.
The historical data trend for Onyx Biotec's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Onyx Biotec's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's ROE % distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Onyx Biotec (NSE:ONYX) has a ROE % of 2.49% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Onyx Biotec and its competitors. This is 80% below median its historical median of 12.25. According to the industry distribution chart, Onyx Biotec ranks #449 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 56.3%.
Is Onyx Biotec's ROE % too high?
Onyx Biotec's current ROE % of 2.49% is 80% below median its 10-year median of 12.25. The Medical Devices & Instruments industry median ROE % is 2.41. Onyx Biotec's value of 2.49% is 3.3% above this industry median. Based on the distribution chart, Onyx Biotec ranks #449 out of 798 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #449 out of 798 companies for ROE %. This places Onyx Biotec in the lower half of its industry. The industry median ROE % is 2.41. Onyx Biotec's value of 2.49% is 3.3% above this benchmark. While the company's 10-year median is 12.25 vs. the industry median of 2.41, Onyx Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.41, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current ROE % of 2.49% is 3.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Onyx Biotec and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current ROE % is 2.49%, which is 80% below median its own 10-year median of 12.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current ROE % of 2.49%. The current ROE % is 2.49%, which is 80% below median its 10-year median of 12.25 and 3.3% above the Medical Devices & Instruments industry median of 2.41. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current ROE % is 2.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score
Get the complete analysis for NSE:ONYX
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 